Dupilumab Drug Survival and Associated Predictors in Patients With Moderate to Severe Atopic Dermatitis: Long-term Results From the Daily Practice BioDay Registry.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA dermatology"
DOI: 10.1001/jamadermatol.2022.3014
Abstract: Importance Long-term data on dupilumab drug survival in patients with atopic dermatitis (AD) are scarce. Furthermore, little is known about the factors associated with drug survival of dupilumab in AD. Objective To describe the drug… read more here.
Keywords: year; drug survival; bioday registry; dupilumab drug ... See more keywords
Use of biological disease modifying antirheumatic drugs in rheumatoid arthritis in Austria from 2008 to 2011
Sign Up to like & getrecommendations! Published in 2018 at "Wiener klinische Wochenschrift"
DOI: 10.1007/s00508-018-1321-4
Abstract: SummaryBackgroundRheumatoid arthritis (RA) is the most prevalent chronic inflammatory joint disease. On a national level in Austria, there are currently no data available on how often and which biological disease modifying antirheumatic drugs (bDMARDs) are prescribed… read more here.
Keywords: modifying antirheumatic; drug survival; disease modifying; biological disease ... See more keywords
Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2019.02.031
Abstract: To the Editor: Secukinumab, an interleukin 17A inhibitor approved for the treatment of moderate-tosevere plaque psoriasis, has shown high levels of clinical efficacy and a favorable safety profile in both short-term and long-term clinical trials.… read more here.
Keywords: drug survival; study; drug; secukinumab drug ... See more keywords
Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Sign Up to like & getrecommendations! Published in 2017 at "Seminars in arthritis and rheumatism"
DOI: 10.1016/j.semarthrit.2017.01.008
Abstract: OBJECTIVES To assess the drug survival of golimumab, and predictors thereof, in patients affected with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA) in a prospective observational cohort. METHODS This is a non-interventional, longitudinal… read more here.
Keywords: drug survival; golimumab; drug; discontinuation ... See more keywords
Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Dermatological Treatment"
DOI: 10.1080/09546634.2022.2082354
Abstract: Abstract Background Real-world data on the use of interleukin-17 (IL-17) inhibitors for the treatment of psoriasis are limited. Objective To evaluate and compare the efficacy, safety, and drug survival of IL-17 inhibitors. Methods This retrospective… read more here.
Keywords: safety; secukinumab; drug survival; ixekizumab secukinumab ... See more keywords
Age and psoriatic arthritis are important predictors of biologic agent switch in psoriasis.
Sign Up to like & getrecommendations! Published in 2021 at "Expert review of clinical pharmacology"
DOI: 10.1080/17512433.2021.1979394
Abstract: BACKGROUND The demand of biologic switching is increasing for different reasons. We aimed to define reasons for switching biologics and possible predictors for switching risk, and to estimate data on drug survival. METHODS One-hundred and… read more here.
Keywords: psoriatic arthritis; line; drug survival; drug ... See more keywords
P548 Drug Survival in Patients with Inflammatory Bowel disease: An observational study
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab076.669
Abstract: Although the therapeutic array has significantly widened, over the past decades predicting treatment persistence in IBD patients is still a challenge. In this study we collected longitudinal data to determine drug survival on the medications… read more here.
Keywords: patients still; study; year; drug survival ... See more keywords
Drug-Survival Profiling of Second-Line Biologic Therapy in Rheumatoid Arthritis: Choice of Another TNFi or a Biologic of Different Mode of Action?
Sign Up to like & getrecommendations! Published in 2022 at "Modern rheumatology"
DOI: 10.1093/mr/roac086
Abstract: OBJECTIVES Aiming to assess the best choice of second-line therapy between second-line TNF-inhibitor (TNFi) and biologics of different mode of action (BDMA-rituximab/tocilizumab/abatacept) in rheumatoid arthritis (RA) by assessing their drug-survival spanning more that 10years, after… read more here.
Keywords: survival; drug survival; tnfi; line ... See more keywords
Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry.
Sign Up to like & getrecommendations! Published in 2021 at "Rheumatology"
DOI: 10.1093/rheumatology/keab419
Abstract: OBJECTIVES To investigate survival of interleukin (IL)-1 inhibitors in monogenic autoinflammatory disorders (mAID) through drug retention rate (DRR) and identify potential predictive factors of drug survival from a real-life perspective. PATIENTS AND METHODS Multicentre retrospective… read more here.
Keywords: anakinra canakinumab; drug survival; treatment; monogenic autoinflammatory ... See more keywords
Drug survival of thalidomide for dermatological conditions: A single‐centre review
Sign Up to like & getrecommendations! Published in 2020 at "Australasian Journal of Dermatology"
DOI: 10.1111/ajd.13384
Abstract: Thalidomide is an immunomodulatory drug which has demonstrated success across several refractory dermatological conditions. Its mechanism remains poorly understood and is uncommonly prescribed in the field of dermatology, usually as a last-line therapeutic option. Historically,… read more here.
Keywords: dermatology; drug survival; survival thalidomide; drug ... See more keywords
Drug survival of methotrexate in psoriasis
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Dermatology"
DOI: 10.1111/bjd.15693
Abstract: 1 Talamonti M, Galluzzo M, van den Reek JM et al. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br J Dermatol… read more here.
Keywords: psoriasis; invest dermatol; drug survival; survival methotrexate ... See more keywords